- In October 2022, BD, a global medical technology company, and Magnolia Medical Technologies, Inc. entered a commercial agreement aimed at helping U.S. hospitals reduce blood culture contamination. This collaboration seeks to enhance testing accuracy and improve clinical outcomes by preventing contamination
- In August 2022, Immunexpress, Pty Ltd., a molecular diagnostic company, launched the SeptiCyte RAPID EDTA blood-compatible cartridges in Europe. This new, advanced cartridge is the first-to-market host response technology that uses undiluted EDTA blood as a validated sample type, marking a significant development in sepsis diagnostics
- In July 2022, T2 Biosystems, Inc., a leader in the early detection of sepsis-causing antibiotic resistance genes and microorganisms, received a grant from the U.S. Food and Drug Administration (FDA) for their T2Lyme panel. This panel helps physicians quickly administer appropriate therapy, preventing both the adverse effects of incorrect treatment and the overuse of antibiotics
- In March 2022, Accelerate Diagnostics, Inc., an in-vitro diagnostics company, introduced the Accelerate Arc system, which includes the Arc Module and BC Kit. This system automates the rapid and accurate identification of microorganisms in positive blood cultures
- In June 2021, Accelerate Diagnostics, a biotech firm based in Tucson, Arizona, received up to USD 578,000 in funding from CARB-X to support the development of innovative fiber optic technology aimed at diagnosing or assessing the risk of sepsis
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (Consumables, Instruments, and Software),Technique (Conventional, PCR Methods, Nucleic Acid Testing, Mass Spectroscopy, and POC Testing),Technology (Culture-based and Molecular Proteomic), Application (Hospital Acquired and Community Based), Type (Bacterial, Fungal, and Mycobacterial), End User (Hospitals, Healthcare Centers, Laboratories, Independent Diagnostic Centers, and Research or Academic Institutes) – Industry Trends and Forecast to 2032
.
The Global Bloodstream Infection Testing Market size was valued at USD 1.20 USD Billion in 2024.
The Global Bloodstream Infection Testing Market is projected to grow at a CAGR of 5.76% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
